|
|
VANCOUVER, BC / ACCESSWIRE / October 24, 2023 / MindBio Therapeutics Corp. CSE:MBIO; Frankfurt:WF6, the "Company" or "MindBio", Chief Executive Officer Justin Hanka provides video update on Phase 2a Depression trial using MB22001. MindBio is pleased to report that dosing is progressing well in its Phase 2a Depression trial using MB22001 MindBios proprietary titratable form of... Lire le communiqué |
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / October 5, 2023 / MindBio Therapeutics Corp. CSE:MBIO; Frankfurt:WF6, the "Company" or "MindBio", is pleased to announce that the first ten clinical trial participants out of a total of 20 anticipated participants with depression have started take home dosing of MB22001 in the Companys Phase 2a clinical trial.... Lire le communiqué |
|
| |
|
| |
|
|
VANCOUVER, BC / ACCESSWIRE / September 14, 2023 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", Chief Executive Officer Justin Hanka provides corporate update on depression trials and other important developments in the Company in this video address to shareholders.In this video, Justin Hanka, Chief Executive Officer of MindBio,... Lire le communiqué |
|
| |
|
| |
|
|
Genetic Discovery: MindBios genetic testing in clinical research yields novel discovery for targeted diagnosis and treatmentSignificant Intellectual Property & Know HowWorldfirst approvals for takehome microdosing in clinical trialsVANCOUVER, BC / ACCESSWIRE / September 5, 2023 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Comp... Lire le communiqué |
|
| |
|
| |
|
|
Worldfirst takehome approvalsThe first doses of MB22001 have been administered in an 8 week treatment protocolVANCOUVER, BC / ACCESSWIRE / August 24, 2023 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", is pleased to announce the first doses of MB22001 have been administered to patients... Lire le communiqué |
|
| |
|
| |
|
|
MB22001 has been manufactured ready for use in Phase 2 clinical trialsWorld first takehome approvals for psychedelic microdosingVANCOUVER, BC / ACCESSWIRE / August 18, 2023 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio", is excited to announce it has received its first batch of MB22001 ready for takehom... Lire le communiqué |
|
| |
|
| |
|
|
MindBio and Cofounders profiled in Australian Financial ReviewRegulatory changes in Australia arrive 1 July 2023CEO lands in Canada for investor and conference presentationsVANCOUVER, BC / ACCESSWIRE / June 9, 2023 / MindBio Therapeutics Corp. CSE:MBIOFrankfurt:WF6, the "Company" or "MindBio",... Lire le communiqué |
|
| |
|
| |
